Harrison Bai
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Intelligence | 15 | 2025 | 381 | 3.810 |
Why?
| | Image Processing, Computer-Assisted | 14 | 2026 | 783 | 3.700 |
Why?
| | Magnetic Resonance Imaging | 33 | 2026 | 3916 | 2.820 |
Why?
| | Machine Learning | 11 | 2025 | 587 | 2.670 |
Why?
| | Positron Emission Tomography Computed Tomography | 4 | 2025 | 118 | 2.330 |
Why?
| | Brain Neoplasms | 24 | 2024 | 1331 | 2.240 |
Why?
| | Glioma | 18 | 2022 | 429 | 2.080 |
Why?
| | Kidney Neoplasms | 6 | 2025 | 415 | 1.920 |
Why?
| | Tomography, X-Ray Computed | 16 | 2025 | 2770 | 1.720 |
Why?
| | Liver Neoplasms | 7 | 2023 | 777 | 1.720 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2023 | 373 | 1.500 |
Why?
| | Carcinoma, Renal Cell | 5 | 2021 | 230 | 1.460 |
Why?
| | Image Interpretation, Computer-Assisted | 6 | 2026 | 289 | 1.450 |
Why?
| | Radiologists | 3 | 2021 | 61 | 1.360 |
Why?
| | Diagnostic Imaging | 2 | 2025 | 337 | 1.120 |
Why?
| | Urea | 2 | 2025 | 85 | 1.090 |
Why?
| | Prostatic Neoplasms | 2 | 2025 | 981 | 1.030 |
Why?
| | Humans | 140 | 2026 | 145783 | 1.020 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 391 | 0.970 |
Why?
| | Coronavirus Infections | 3 | 2020 | 384 | 0.970 |
Why?
| | Lysine | 2 | 2025 | 305 | 0.940 |
Why?
| | Retrospective Studies | 40 | 2025 | 17330 | 0.940 |
Why?
| | Chemoembolization, Therapeutic | 2 | 2023 | 89 | 0.930 |
Why?
| | Bayes Theorem | 3 | 2025 | 421 | 0.890 |
Why?
| | Multimodal Imaging | 2 | 2025 | 129 | 0.870 |
Why?
| | Stroke | 6 | 2022 | 1271 | 0.860 |
Why?
| | Cerebellar Neoplasms | 3 | 2022 | 177 | 0.860 |
Why?
| | Aged | 43 | 2025 | 26217 | 0.800 |
Why?
| | Lung Neoplasms | 6 | 2023 | 2668 | 0.790 |
Why?
| | Algorithms | 12 | 2026 | 1851 | 0.790 |
Why?
| | Neoplasms | 5 | 2025 | 2913 | 0.770 |
Why?
| | Radiography, Thoracic | 2 | 2021 | 172 | 0.760 |
Why?
| | Betacoronavirus | 3 | 2020 | 289 | 0.750 |
Why?
| | Medulloblastoma | 2 | 2022 | 215 | 0.730 |
Why?
| | Middle Aged | 47 | 2025 | 36309 | 0.720 |
Why?
| | Biomedical Research | 2 | 2022 | 719 | 0.720 |
Why?
| | Osteoarthritis, Knee | 2 | 2016 | 281 | 0.720 |
Why?
| | Databases, Factual | 13 | 2024 | 1491 | 0.710 |
Why?
| | Radiography | 4 | 2022 | 853 | 0.700 |
Why?
| | Female | 74 | 2025 | 79045 | 0.680 |
Why?
| | Bone Neoplasms | 2 | 2021 | 265 | 0.680 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2022 | 148 | 0.660 |
Why?
| | Astrocytoma | 3 | 2018 | 130 | 0.660 |
Why?
| | Ovarian Cysts | 1 | 2020 | 6 | 0.660 |
Why?
| | Awards and Prizes | 1 | 2022 | 71 | 0.660 |
Why?
| | Cholangiocarcinoma | 1 | 2022 | 108 | 0.650 |
Why?
| | Prognosis | 15 | 2025 | 4330 | 0.650 |
Why?
| | Male | 66 | 2025 | 73010 | 0.640 |
Why?
| | Radiology | 2 | 2021 | 174 | 0.640 |
Why?
| | Bile Duct Neoplasms | 1 | 2022 | 131 | 0.640 |
Why?
| | Data Anonymization | 1 | 2020 | 1 | 0.630 |
Why?
| | Computed Tomography Angiography | 4 | 2025 | 146 | 0.620 |
Why?
| | Isocitrate Dehydrogenase | 6 | 2019 | 72 | 0.600 |
Why?
| | Head | 2 | 2020 | 123 | 0.600 |
Why?
| | Brain Ischemia | 2 | 2022 | 359 | 0.590 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 4 | 2021 | 1192 | 0.580 |
Why?
| | Oligodendroglioma | 2 | 2016 | 15 | 0.580 |
Why?
| | Biopsy | 5 | 2018 | 1082 | 0.570 |
Why?
| | Parkinson Disease | 1 | 2025 | 601 | 0.560 |
Why?
| | Pulmonary Embolism | 3 | 2025 | 241 | 0.550 |
Why?
| | Aged, 80 and over | 21 | 2025 | 8347 | 0.550 |
Why?
| | Dizziness | 2 | 2016 | 101 | 0.540 |
Why?
| | Liver Diseases | 1 | 2021 | 305 | 0.540 |
Why?
| | Sensitivity and Specificity | 6 | 2025 | 2000 | 0.530 |
Why?
| | Diagnosis, Differential | 7 | 2020 | 1512 | 0.500 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2933 | 0.500 |
Why?
| | Neoplasm Grading | 8 | 2020 | 311 | 0.490 |
Why?
| | Brain | 9 | 2026 | 2969 | 0.490 |
Why?
| | Polyarteritis Nodosa | 1 | 2016 | 11 | 0.490 |
Why?
| | Early Diagnosis | 2 | 2025 | 251 | 0.480 |
Why?
| | Polymyalgia Rheumatica | 1 | 2015 | 3 | 0.470 |
Why?
| | Rotator Cuff | 1 | 2016 | 59 | 0.470 |
Why?
| | Unsupervised Machine Learning | 2 | 2026 | 23 | 0.470 |
Why?
| | Whole Body Imaging | 1 | 2015 | 29 | 0.460 |
Why?
| | ROC Curve | 4 | 2021 | 618 | 0.460 |
Why?
| | Prednisolone | 1 | 2015 | 67 | 0.460 |
Why?
| | Patella | 1 | 2015 | 28 | 0.450 |
Why?
| | Vertigo | 1 | 2016 | 55 | 0.450 |
Why?
| | Glutamate Carboxypeptidase II | 2 | 2025 | 8 | 0.440 |
Why?
| | Adult | 35 | 2025 | 40881 | 0.440 |
Why?
| | Postoperative Care | 2 | 2019 | 286 | 0.440 |
Why?
| | Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase | 1 | 2014 | 1 | 0.440 |
Why?
| | Diagnostic Errors | 1 | 2016 | 178 | 0.440 |
Why?
| | Physical Examination | 1 | 2016 | 244 | 0.440 |
Why?
| | Cerebrovascular Disorders | 1 | 2016 | 105 | 0.440 |
Why?
| | Knee Joint | 2 | 2016 | 429 | 0.430 |
Why?
| | Rare Diseases | 1 | 2015 | 116 | 0.430 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 2014 | 16 | 0.430 |
Why?
| | Antigens, Surface | 2 | 2025 | 155 | 0.420 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 3 | 2025 | 122 | 0.420 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 596 | 0.420 |
Why?
| | Coronary Artery Bypass | 1 | 2016 | 268 | 0.400 |
Why?
| | Thrombolytic Therapy | 1 | 2015 | 164 | 0.400 |
Why?
| | Genomics | 2 | 2016 | 830 | 0.400 |
Why?
| | Radiology Information Systems | 2 | 2025 | 35 | 0.390 |
Why?
| | Chordoma | 3 | 2018 | 17 | 0.380 |
Why?
| | Positron-Emission Tomography | 3 | 2022 | 343 | 0.370 |
Why?
| | Neoplasm Staging | 7 | 2021 | 1475 | 0.370 |
Why?
| | Radiation Injuries | 2 | 2025 | 149 | 0.370 |
Why?
| | Chromosome Deletion | 3 | 2018 | 126 | 0.360 |
Why?
| | Young Adult | 19 | 2025 | 14254 | 0.360 |
Why?
| | Nervous System Diseases | 1 | 2015 | 286 | 0.360 |
Why?
| | Tumor Burden | 4 | 2022 | 325 | 0.350 |
Why?
| | Proportional Hazards Models | 9 | 2021 | 1330 | 0.350 |
Why?
| | Clinical Competence | 1 | 2020 | 1247 | 0.340 |
Why?
| | Cartilage, Articular | 1 | 2015 | 349 | 0.340 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2025 | 104 | 0.340 |
Why?
| | Radiotherapy, Adjuvant | 4 | 2019 | 222 | 0.340 |
Why?
| | Neuroimaging | 4 | 2026 | 300 | 0.330 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3418 | 0.330 |
Why?
| | Adipose Tissue | 1 | 2015 | 645 | 0.330 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2016 | 376 | 0.330 |
Why?
| | Skin Neoplasms | 4 | 2018 | 853 | 0.320 |
Why?
| | Chromosomes, Human, Pair 19 | 4 | 2019 | 27 | 0.320 |
Why?
| | Chromosomes, Human, Pair 1 | 4 | 2019 | 80 | 0.310 |
Why?
| | China | 3 | 2020 | 274 | 0.290 |
Why?
| | Meningeal Neoplasms | 2 | 2020 | 95 | 0.290 |
Why?
| | Adolescent | 20 | 2025 | 22577 | 0.290 |
Why?
| | Ablation Techniques | 2 | 2019 | 36 | 0.280 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2022 | 161 | 0.280 |
Why?
| | Predictive Value of Tests | 8 | 2025 | 2123 | 0.280 |
Why?
| | Cerebrospinal Fluid Shunts | 2 | 2025 | 34 | 0.280 |
Why?
| | Child | 14 | 2024 | 22740 | 0.280 |
Why?
| | United States | 12 | 2022 | 16126 | 0.270 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2018 | 45 | 0.270 |
Why?
| | Lymphoproliferative Disorders | 2 | 2018 | 59 | 0.270 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 63 | 0.270 |
Why?
| | Ependymoma | 2 | 2024 | 176 | 0.270 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2019 | 427 | 0.260 |
Why?
| | Pneumonia | 3 | 2023 | 636 | 0.250 |
Why?
| | Gray Matter | 2 | 2024 | 92 | 0.250 |
Why?
| | Spinal Cord Neoplasms | 2 | 2018 | 41 | 0.240 |
Why?
| | Spinal Neoplasms | 2 | 2017 | 37 | 0.240 |
Why?
| | Biomarkers, Tumor | 5 | 2019 | 1329 | 0.240 |
Why?
| | Prospective Studies | 6 | 2025 | 8078 | 0.240 |
Why?
| | Chemoradiotherapy | 2 | 2018 | 239 | 0.240 |
Why?
| | Diagnosis, Computer-Assisted | 3 | 2023 | 92 | 0.230 |
Why?
| | Head and Neck Neoplasms | 2 | 2023 | 561 | 0.230 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 2 | 2017 | 11 | 0.230 |
Why?
| | Propensity Score | 4 | 2019 | 377 | 0.220 |
Why?
| | Treatment Outcome | 14 | 2024 | 11794 | 0.220 |
Why?
| | Aortic Rupture | 1 | 2025 | 27 | 0.220 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2025 | 59 | 0.220 |
Why?
| | Survival Rate | 9 | 2019 | 2094 | 0.220 |
Why?
| | Hydrocephalus, Normal Pressure | 1 | 2024 | 3 | 0.220 |
Why?
| | Contrast Media | 3 | 2023 | 497 | 0.210 |
Why?
| | Temporal Lobe | 1 | 2025 | 107 | 0.210 |
Why?
| | Hydrocephalus | 1 | 2025 | 111 | 0.210 |
Why?
| | Mutation | 6 | 2021 | 4090 | 0.210 |
Why?
| | Ethiodized Oil | 1 | 2023 | 10 | 0.200 |
Why?
| | Child, Preschool | 9 | 2024 | 11868 | 0.200 |
Why?
| | Cerebral Hemorrhage | 1 | 2024 | 125 | 0.200 |
Why?
| | Disease Progression | 4 | 2025 | 2865 | 0.200 |
Why?
| | Thymus Neoplasms | 1 | 2023 | 30 | 0.200 |
Why?
| | Philadelphia | 2 | 2020 | 55 | 0.200 |
Why?
| | Stents | 2 | 2019 | 564 | 0.200 |
Why?
| | Cerium | 1 | 2023 | 14 | 0.200 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2025 | 167 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2024 | 76 | 0.190 |
Why?
| | Cohort Studies | 8 | 2022 | 6033 | 0.190 |
Why?
| | Uncertainty | 1 | 2024 | 146 | 0.190 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2023 | 52 | 0.190 |
Why?
| | Delirium | 1 | 2024 | 105 | 0.190 |
Why?
| | Pandemics | 3 | 2020 | 1711 | 0.190 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 76 | 0.190 |
Why?
| | White Matter | 1 | 2024 | 155 | 0.180 |
Why?
| | Abdomen | 1 | 2023 | 142 | 0.180 |
Why?
| | Skin | 2 | 2017 | 754 | 0.180 |
Why?
| | Middle Cerebral Artery | 1 | 2022 | 56 | 0.180 |
Why?
| | Supervised Machine Learning | 1 | 2022 | 23 | 0.180 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2022 | 63 | 0.180 |
Why?
| | Thrombectomy | 1 | 2022 | 78 | 0.180 |
Why?
| | Radiology, Interventional | 1 | 2022 | 49 | 0.170 |
Why?
| | Financing, Organized | 1 | 2022 | 36 | 0.170 |
Why?
| | Financing, Government | 1 | 2022 | 53 | 0.170 |
Why?
| | Research Support as Topic | 1 | 2022 | 81 | 0.170 |
Why?
| | Pain | 2 | 2018 | 791 | 0.170 |
Why?
| | Rectal Neoplasms | 1 | 2023 | 159 | 0.170 |
Why?
| | Endometrium | 1 | 2021 | 64 | 0.170 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 979 | 0.170 |
Why?
| | Radiosurgery | 3 | 2019 | 399 | 0.170 |
Why?
| | Liver Function Tests | 1 | 2021 | 105 | 0.170 |
Why?
| | Follow-Up Studies | 9 | 2020 | 5428 | 0.160 |
Why?
| | Severe Acute Respiratory Syndrome | 1 | 2020 | 19 | 0.160 |
Why?
| | Seizures | 2 | 2015 | 485 | 0.160 |
Why?
| | Uterine Artery Embolization | 1 | 2020 | 9 | 0.160 |
Why?
| | Rhode Island | 1 | 2020 | 31 | 0.160 |
Why?
| | Survival Analysis | 5 | 2024 | 1378 | 0.160 |
Why?
| | Angiography, Digital Subtraction | 1 | 2020 | 48 | 0.160 |
Why?
| | Kidney | 2 | 2025 | 1497 | 0.150 |
Why?
| | Disease-Free Survival | 5 | 2020 | 770 | 0.150 |
Why?
| | Brain Diseases | 1 | 2021 | 155 | 0.150 |
Why?
| | Adenocarcinoma, Sebaceous | 1 | 2019 | 2 | 0.150 |
Why?
| | Necrosis | 1 | 2021 | 244 | 0.150 |
Why?
| | Sebaceous Gland Neoplasms | 1 | 2019 | 3 | 0.150 |
Why?
| | Arteriovenous Fistula | 1 | 2020 | 38 | 0.150 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2020 | 53 | 0.150 |
Why?
| | Leiomyoma | 1 | 2020 | 61 | 0.150 |
Why?
| | Anastomotic Leak | 1 | 2019 | 45 | 0.150 |
Why?
| | Mohs Surgery | 1 | 2019 | 29 | 0.150 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2019 | 23 | 0.150 |
Why?
| | Motor Cortex | 1 | 2020 | 65 | 0.150 |
Why?
| | Colon | 1 | 2022 | 309 | 0.150 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.150 |
Why?
| | Uterine Neoplasms | 1 | 2020 | 98 | 0.150 |
Why?
| | Patient Admission | 1 | 2021 | 220 | 0.150 |
Why?
| | Cryosurgery | 1 | 2019 | 46 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2025 | 468 | 0.140 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 467 | 0.140 |
Why?
| | Hemangioblastoma | 1 | 2018 | 3 | 0.140 |
Why?
| | Nomograms | 3 | 2025 | 59 | 0.140 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2018 | 17 | 0.140 |
Why?
| | Neurofibroma, Plexiform | 1 | 2018 | 12 | 0.140 |
Why?
| | Osteolysis, Essential | 1 | 2018 | 2 | 0.140 |
Why?
| | Face | 1 | 2020 | 175 | 0.140 |
Why?
| | Lung | 3 | 2021 | 4116 | 0.140 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2018 | 32 | 0.140 |
Why?
| | Mesentery | 1 | 2018 | 44 | 0.140 |
Why?
| | Meningioma | 1 | 2019 | 88 | 0.140 |
Why?
| | Lymphoma, T-Cell | 1 | 2018 | 30 | 0.140 |
Why?
| | DNA Repair Enzymes | 1 | 2018 | 29 | 0.140 |
Why?
| | Radiography, Interventional | 1 | 2019 | 128 | 0.140 |
Why?
| | Cumulative Trauma Disorders | 1 | 2018 | 30 | 0.140 |
Why?
| | Skull Base Neoplasms | 1 | 2018 | 30 | 0.130 |
Why?
| | Journal Impact Factor | 1 | 2018 | 29 | 0.130 |
Why?
| | Clavicle | 1 | 2018 | 38 | 0.130 |
Why?
| | Pneumonectomy | 1 | 2019 | 167 | 0.130 |
Why?
| | Gastric Bypass | 1 | 2019 | 126 | 0.130 |
Why?
| | Esophageal Neoplasms | 1 | 2022 | 348 | 0.130 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2017 | 20 | 0.130 |
Why?
| | Acute Lung Injury | 1 | 2021 | 307 | 0.130 |
Why?
| | Risk Factors | 6 | 2025 | 10919 | 0.130 |
Why?
| | Publications | 1 | 2018 | 47 | 0.130 |
Why?
| | Peritoneal Neoplasms | 1 | 2018 | 104 | 0.130 |
Why?
| | Histiocytosis | 1 | 2017 | 9 | 0.130 |
Why?
| | Neurosurgical Procedures | 1 | 2019 | 202 | 0.130 |
Why?
| | Embolization, Therapeutic | 1 | 2020 | 243 | 0.130 |
Why?
| | Subclavian Steal Syndrome | 1 | 2017 | 3 | 0.130 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 237 | 0.130 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 195 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2023 | 883 | 0.130 |
Why?
| | Biomarkers | 3 | 2023 | 4302 | 0.120 |
Why?
| | Nanoparticles | 1 | 2023 | 517 | 0.120 |
Why?
| | Ultrasonography | 1 | 2021 | 788 | 0.120 |
Why?
| | Insurance Coverage | 1 | 2018 | 244 | 0.120 |
Why?
| | Health Resources | 1 | 2018 | 130 | 0.120 |
Why?
| | Models, Statistical | 2 | 2025 | 672 | 0.120 |
Why?
| | Radiotherapy | 1 | 2017 | 206 | 0.120 |
Why?
| | RNA, Viral | 1 | 2020 | 693 | 0.120 |
Why?
| | False Positive Reactions | 1 | 2016 | 123 | 0.120 |
Why?
| | Hot Temperature | 1 | 2019 | 396 | 0.120 |
Why?
| | Toxoplasmosis, Cerebral | 1 | 2016 | 2 | 0.120 |
Why?
| | Vertebrobasilar Insufficiency | 1 | 2016 | 10 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1662 | 0.120 |
Why?
| | Brain Mapping | 2 | 2020 | 542 | 0.120 |
Why?
| | Hepatectomy | 1 | 2018 | 274 | 0.120 |
Why?
| | Spine | 1 | 2017 | 182 | 0.120 |
Why?
| | AIDS Dementia Complex | 1 | 2016 | 52 | 0.120 |
Why?
| | Time Factors | 4 | 2020 | 7134 | 0.120 |
Why?
| | Superior Mesenteric Artery Syndrome | 1 | 2015 | 8 | 0.120 |
Why?
| | Insurance, Health | 1 | 2018 | 311 | 0.110 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 38 | 0.110 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2015 | 16 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 4 | 2019 | 971 | 0.110 |
Why?
| | Lymphoma | 1 | 2017 | 241 | 0.110 |
Why?
| | Cushing Syndrome | 1 | 2015 | 10 | 0.110 |
Why?
| | Central Nervous System Diseases | 1 | 2016 | 74 | 0.110 |
Why?
| | Epilepsy, Absence | 1 | 2015 | 12 | 0.110 |
Why?
| | Chronic Disease | 1 | 2021 | 1812 | 0.110 |
Why?
| | Accessory Nerve Diseases | 1 | 2014 | 1 | 0.110 |
Why?
| | Hypoglossal Nerve Diseases | 1 | 2014 | 3 | 0.110 |
Why?
| | Epilepsy | 2 | 2017 | 390 | 0.110 |
Why?
| | Central Nervous System Neoplasms | 1 | 2017 | 177 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2021 | 948 | 0.110 |
Why?
| | Oxygen | 1 | 2020 | 981 | 0.110 |
Why?
| | Abdominal Pain | 1 | 2015 | 149 | 0.100 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2017 | 627 | 0.100 |
Why?
| | Critical Illness | 1 | 2021 | 900 | 0.100 |
Why?
| | Antineoplastic Agents | 2 | 2023 | 2219 | 0.100 |
Why?
| | Hypertension | 1 | 2023 | 1276 | 0.100 |
Why?
| | MicroRNAs | 2 | 2017 | 686 | 0.100 |
Why?
| | Liver Cirrhosis | 1 | 2016 | 288 | 0.100 |
Why?
| | Patient Discharge | 1 | 2020 | 995 | 0.100 |
Why?
| | Paresis | 1 | 2013 | 30 | 0.100 |
Why?
| | Oligodendroglia | 1 | 2016 | 190 | 0.100 |
Why?
| | Risk Assessment | 3 | 2021 | 3752 | 0.100 |
Why?
| | Encephalitis | 1 | 2015 | 142 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2013 | 50 | 0.100 |
Why?
| | Hydroa Vacciniforme | 1 | 2013 | 1 | 0.100 |
Why?
| | Puerperal Disorders | 1 | 2013 | 36 | 0.100 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2013 | 71 | 0.090 |
Why?
| | Periodicals as Topic | 1 | 2015 | 209 | 0.090 |
Why?
| | Fractures, Bone | 1 | 2018 | 428 | 0.090 |
Why?
| | Infant, Newborn | 2 | 2025 | 6465 | 0.090 |
Why?
| | Ischemia | 1 | 2016 | 422 | 0.090 |
Why?
| | CD4 Antigens | 1 | 2013 | 137 | 0.090 |
Why?
| | Anticonvulsants | 1 | 2015 | 246 | 0.090 |
Why?
| | Area Under Curve | 2 | 2024 | 332 | 0.090 |
Why?
| | Precision Medicine | 1 | 2016 | 461 | 0.090 |
Why?
| | Surgeons | 1 | 2016 | 340 | 0.090 |
Why?
| | HIV Infections | 2 | 2017 | 3195 | 0.080 |
Why?
| | Schizophrenia | 1 | 2015 | 464 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1062 | 0.080 |
Why?
| | Postpartum Period | 1 | 2013 | 373 | 0.080 |
Why?
| | Craniotomy | 2 | 2020 | 84 | 0.070 |
Why?
| | Infant | 2 | 2020 | 10091 | 0.070 |
Why?
| | Clinical Decision-Making | 2 | 2024 | 364 | 0.070 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2015 | 1150 | 0.070 |
Why?
| | Pregnancy Complications | 1 | 2013 | 603 | 0.060 |
Why?
| | Incidence | 3 | 2021 | 2934 | 0.060 |
Why?
| | Age Factors | 3 | 2018 | 3346 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1547 | 0.050 |
Why?
| | Meningomyelocele | 1 | 2025 | 62 | 0.050 |
Why?
| | Aorta, Abdominal | 1 | 2025 | 52 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 1271 | 0.050 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2024 | 44 | 0.050 |
Why?
| | Phenylphosphonothioic Acid, 2-Ethyl 2-(4-Nitrophenyl) Ester | 1 | 2024 | 1 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2019 | 1327 | 0.050 |
Why?
| | Adenocarcinoma | 2 | 2021 | 926 | 0.050 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 39 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2016 | 2977 | 0.050 |
Why?
| | Stress, Mechanical | 1 | 2025 | 494 | 0.050 |
Why?
| | X-Rays | 1 | 2022 | 27 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 241 | 0.040 |
Why?
| | Rectum | 1 | 2023 | 182 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 1 | 2025 | 583 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2025 | 860 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2023 | 280 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2022 | 501 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 479 | 0.040 |
Why?
| | Gene Expression | 1 | 2025 | 1478 | 0.040 |
Why?
| | Color | 1 | 2020 | 81 | 0.040 |
Why?
| | Anal Canal | 1 | 2020 | 102 | 0.040 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1998 | 0.040 |
Why?
| | Electrocardiography | 1 | 2023 | 668 | 0.040 |
Why?
| | Antioxidants | 1 | 2023 | 550 | 0.040 |
Why?
| | Automation | 1 | 2019 | 104 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 50 | 0.040 |
Why?
| | Sulfonamides | 1 | 2023 | 583 | 0.040 |
Why?
| | Observer Variation | 1 | 2020 | 357 | 0.040 |
Why?
| | Research | 1 | 2022 | 431 | 0.040 |
Why?
| | Fluoroscopy | 1 | 2019 | 180 | 0.040 |
Why?
| | Body Composition | 1 | 2023 | 693 | 0.040 |
Why?
| | Fever | 1 | 2020 | 320 | 0.040 |
Why?
| | Perfusion | 1 | 2020 | 251 | 0.030 |
Why?
| | Drainage | 1 | 2019 | 185 | 0.030 |
Why?
| | Cranial Fossa, Posterior | 1 | 2018 | 20 | 0.030 |
Why?
| | Ki-1 Antigen | 1 | 2018 | 7 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2025 | 630 | 0.030 |
Why?
| | Neuroendoscopy | 1 | 2018 | 24 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2018 | 83 | 0.030 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2018 | 23 | 0.030 |
Why?
| | Societies, Medical | 1 | 2022 | 900 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2021 | 635 | 0.030 |
Why?
| | Neurosurgery | 1 | 2018 | 41 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 486 | 0.030 |
Why?
| | Age of Onset | 1 | 2019 | 557 | 0.030 |
Why?
| | Hospitalization | 2 | 2020 | 2461 | 0.030 |
Why?
| | Atlases as Topic | 1 | 2017 | 10 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2017 | 118 | 0.030 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2017 | 21 | 0.030 |
Why?
| | Organ Specificity | 1 | 2018 | 309 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2025 | 2181 | 0.030 |
Why?
| | Neck | 1 | 2017 | 109 | 0.030 |
Why?
| | Preoperative Period | 1 | 2017 | 149 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2018 | 528 | 0.030 |
Why?
| | Putamen | 1 | 2017 | 23 | 0.030 |
Why?
| | Extremities | 1 | 2017 | 142 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2018 | 887 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1969 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2139 | 0.030 |
Why?
| | Perioperative Period | 1 | 2016 | 71 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 1083 | 0.030 |
Why?
| | Pain Measurement | 1 | 2018 | 562 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2410 | 0.030 |
Why?
| | Tyrosine | 1 | 2016 | 217 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2022 | 924 | 0.030 |
Why?
| | Hospitals | 1 | 2020 | 733 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2016 | 205 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 641 | 0.030 |
Why?
| | Bias | 1 | 2016 | 197 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 442 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 283 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 688 | 0.030 |
Why?
| | Ferrets | 1 | 2015 | 31 | 0.030 |
Why?
| | Genome | 1 | 2017 | 305 | 0.030 |
Why?
| | Hemodynamics | 1 | 2020 | 1118 | 0.030 |
Why?
| | Skull Base | 1 | 2014 | 55 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 508 | 0.030 |
Why?
| | Intracranial Hemorrhages | 1 | 2015 | 106 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2017 | 509 | 0.030 |
Why?
| | Medicaid | 1 | 2018 | 467 | 0.030 |
Why?
| | Hematoma, Epidural, Spinal | 1 | 2013 | 5 | 0.020 |
Why?
| | Cerebral Angiography | 1 | 2013 | 119 | 0.020 |
Why?
| | Sports | 1 | 2015 | 212 | 0.020 |
Why?
| | CD56 Antigen | 1 | 2013 | 34 | 0.020 |
Why?
| | Cervical Vertebrae | 1 | 2014 | 169 | 0.020 |
Why?
| | Risk | 1 | 2015 | 923 | 0.020 |
Why?
| | Valine | 1 | 2013 | 83 | 0.020 |
Why?
| | Medicare | 1 | 2018 | 904 | 0.020 |
Why?
| | Acyclovir | 1 | 2013 | 98 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1139 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 305 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2020 | 2050 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2110 | 0.020 |
Why?
| | Herpesvirus 4, Human | 1 | 2013 | 172 | 0.020 |
Why?
| | Prednisone | 1 | 2013 | 226 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2968 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2013 | 193 | 0.020 |
Why?
| | Electroencephalography | 1 | 2015 | 563 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2016 | 587 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1723 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2015 | 1372 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2015 | 4568 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 7216 | 0.010 |
Why?
| | Animals | 1 | 2015 | 38101 | 0.010 |
Why?
|
|
Bai's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|